Evidence map›Paper›PMID 35950033›Full record

ArticleOpen medicine (Warsaw, Poland)2022

A 16-gene signature associated with homologous recombination deficiency for prognosis prediction in patients with triple-negative breast cancer.

Daodu Wang, Yifeng Shi, Hanyang Huang, Qijiong Zhao, Yongyue He, Wenzhi Su

Open access · goldAbstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daodu WangOncology Center, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.
Yifeng ShiDepartment of General Surgery, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.
Hanyang HuangDepartment of General Surgery, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.
Qijiong ZhaoOncology Center, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.
Yongyue HeOncology Center, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.
Wenzhi SuOncology Center, Shanwei Yihui Fund Hospital (Shanwei Second People's Hospital), Shanwei, 516600, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homologous recombination deficiency (HRD) commonly occurs in breast cancer, which is the second cause of cancer death in women with a high rate of relapse and poor outcomes. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Thus, we aim to develop a prognostic signature based on HRD expecting to help improve outcomes in TNBC. The Cancer Genome Atlas (TCGA)-TNBC cohort was divided into the training set and the testing set randomly. Sixteen genes were filtered from the prognostic HRD-associated genes to establish a prognostic model in the training set. Patients were divided into high-risk and low-risk groups based on the median value of the risk score. Prognosis analysis showed that the high-risk group was associated with a worse prognosis in the training set, the testing set, the entire TCGA-TNBC cohort, and the METABRIC-TNBC cohort. The time-dependent receiver operating characteristic curve showed that our model had very good accuracy in the prediction of 1-5-year overall survival in the TCGA-TNBC cohort. Besides, a comparison of the area under curve value and

Indexed as

breast cancerhomologous recombination deficiencyHRD scoreprognosis modeltriple-negative

Identifiers

PMID35950033
PMCPMC9096232
OpenAlexW4285134219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.